Kristina Finlaw
Primary Care · Pomeroy, OHNPI 1780026658
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,087 and has fallen 89.6% since, to $113 in 2025. Among primary care clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$867
- AstraZeneca$801
- Novo Nordisk$254
- Amgen$246
- Boehringer Ingelheim$233
- Otsuka America Pharmaceutical, Inc.$198
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,905100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $867 |
| AstraZeneca | 27 | $801 |
| Novo Nordisk | 17 | $254 |
| Amgen | 17 | $246 |
| Boehringer Ingelheim | 12 | $233 |
| Otsuka America Pharmaceutical, Inc. | 10 | $198 |
| Lilly USA, LLC | 13 | $189 |
| Pfizer | 9 | $122 |
| Boston Scientific | 1 | $97 |
| Merck | 7 | $97 |
| Corium, LLC | 6 | $92 |
| Johnson & Johnson | 2 | $73 |
| Nestle Healthcare Nutrition Inc. | 5 | $72 |
| Alkermes, Inc. | 4 | $71 |
| Bayer | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Astellas Pharma US Inc | 3 | $41 |
| Abbott | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Intra-sana Laboratories | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$115
How this compares
$3,905 in reported general payments places this provider in the 90th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $119,447 |
| FarxigaDapagliflozin Propanediol | 71 | $98,189 |
| MounjaroTirzepatide | 62 | $94,924 |
| JardianceEmpagliflozin | 37 | $59,273 |
| EliquisApixaban | 43 | $56,200 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $34,067 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $26,077 |
| VraylarCariprazine Hcl | 15 | $21,537 |
| LinzessLinaclotide | 17 | $15,756 |
| KerendiaFinerenone | 11 | $14,440 |
| JanuviaSitagliptin Phosphate | 14 | $13,554 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,343 |
| VascepaIcosapent Ethyl | 12 | $9,106 |
| Repatha SureclickEvolocumab | 11 | $7,172 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $254 | $119,44793 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $801 | $117,490104 claims |
| Lilly USA, LLCMounjaro | $189 | $94,92462 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $233 | $85,34960 claims |
| PfizerEliquis | $122 | $56,20043 claims |
| AbbVieVraylar, Linzess | $867 | $37,29232 claims |
| BayerKerendia | $59 | $14,44011 claims |
| MerckJanuvia | $97 | $13,55414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 321 primary care providers in Ohio.
Other primary care in Pomeroy
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
- Zachary HaleBeavercreek$7K
- Katherine ElliotWesterville$7K
- Stephanie EmmettMayfield Heights$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.